BCWORLD PHARM. Co. Ltd Total Assets
BCWORLD PHARM. Co. Ltd total assets. Based on the latest financial reports, BCWORLD PHARM. Co. Ltd (200780) holds total assets worth ₩173.79 Billion KRW (≈ $117.78 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BCWORLD PHARM. Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of BCWORLD PHARM. Co. Ltd (2015–2024)
Total assets of BCWORLD PHARM. Co. Ltd from 2015 to 2024. This chart illustrates how BCWORLD PHARM. Co. Ltd's total assets have evolved over time, based on quarterly financial data. See BCWORLD PHARM. Co. Ltd share price for real-time trading data and today's change.
BCWORLD PHARM. Co. Ltd - Asset Composition Analysis
BCWORLD PHARM. Co. Ltd Total Assets Breakdown (December 2024)
BCWORLD PHARM. Co. Ltd total assets breakdown as of December 2024. BCWORLD PHARM. Co. Ltd's total assets of ₩173.79 Billion consist of 25.3% current assets and 74.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩5.44 Billion | 0.0% |
| Accounts Receivable | ₩20.34 Billion | 11.5% |
| Inventory | ₩14.84 Billion | 8.4% |
| Property, Plant & Equipment | ₩120.98 Billion | 68.6% |
| Intangible Assets | ₩2.71 Billion | 1.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how BCWORLD PHARM. Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 200780 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BCWORLD PHARM. Co. Ltd's current assets represent 25.3% of total assets in 2024, a decrease from 38.2% in 2015.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 5.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 68.6% of total assets.
BCWORLD PHARM. Co. Ltd Competitors by Total Assets
Key competitors of BCWORLD PHARM. Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €612.64 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
BCWORLD PHARM. Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 0.48 | 0.97 |
| Quick Ratio | 0.30 | 0.29 | 0.50 |
| Cash Ratio | 0.00 | 0.06 | 0.00 |
| Working Capital | ₩-41.34 Billion | ₩-42.06 Billion | ₩-1.83 Billion |
BCWORLD PHARM. Co. Ltd - Advanced Valuation Insights
This section examines the relationship between BCWORLD PHARM. Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | ₩176.31 Billion |
| Market Capitalization | $19.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values BCWORLD PHARM. Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BCWORLD PHARM. Co. Ltd's assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BCWORLD PHARM. Co. Ltd (2015–2024)
The table below shows the annual total assets of BCWORLD PHARM. Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩176.31 Billion ≈ $119.48 Million |
-4.24% |
| 2023-12-31 | ₩184.11 Billion ≈ $124.77 Million |
+0.58% |
| 2022-12-31 | ₩183.05 Billion ≈ $124.05 Million |
+2.06% |
| 2021-12-31 | ₩179.36 Billion ≈ $121.55 Million |
-7.05% |
| 2020-12-31 | ₩192.96 Billion ≈ $130.77 Million |
+11.68% |
| 2019-12-31 | ₩172.78 Billion ≈ $117.09 Million |
+6.82% |
| 2018-12-31 | ₩161.74 Billion ≈ $109.61 Million |
+36.67% |
| 2017-12-31 | ₩118.34 Billion ≈ $80.20 Million |
+22.73% |
| 2016-12-31 | ₩96.42 Billion ≈ $65.34 Million |
+21.50% |
| 2015-12-31 | ₩79.36 Billion ≈ $53.78 Million |
-- |
About BCWORLD PHARM. Co. Ltd
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberc… Read more